Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 19;18(4):595.
doi: 10.3390/ph18040595.

Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study

Nicola Sgherza  1 , Olga Battisti  1 , Paola Curci  1 , Concetta Conticello  2 , Salvatore Palmieri  3 , Daniele Derudas  4 , Candida Germano  5 , Enrica Antonia Martino  6 , Giuseppe Mele  7 , Roberta Della Pepa  8 , Francesca Fazio  9 , Anna Mele  10 , Bernardo Rossini  11 , Giulia Palazzo  12 , Daniela Roccotelli  13 , Simona Rasola  14 , Maria Teresa Petrucci  9 , Domenico Pastore  7 , Giuseppe Tarantini  5 , Fabrizio Pane  8 , Massimo Gentile  6   15 , Francesco Di Raimondo  2   16 , Emanuela Resta  17 , Pellegrino Musto  1   14
Affiliations

Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study

Nicola Sgherza et al. Pharmaceuticals (Basel). .

Erratum in

Abstract

Background: In the randomized, phase-3 IKEMA trial, the triplet isatuximab, carfilzomib, and dexamethasone (IsaKd) demonstrated superior clinical benefit compared to those of carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma after 1-3 prior treatments. Methods: Our real-world, AENEID study aimed to evaluate the efficacy and safety of IsaKd in patients who relapsed after frontline lenalidomide treatment, poorly represented in the IKEMA trial. Specifically, in the present multicenter analysis, we enrolled eighty-two patients who received, between April 2022 and September 2024 and outside of clinical trials, at least one cycle of IsaKd as a second-line treatment at the first relapse after induction therapy, autologous stem cell transplantation (ASCT), and lenalidomide maintenance. Results: After a median follow-up time of 12.9 months (range, 1-77), the overall response rate, at least a very good partial response rate, and median progression-free survival time were 79.3%, 56.1%, and 24.4 months, respectively. This slightly lower performance compared to that in the IKEMA study may be attributed to the well-known poor prognostic impact of lenalidomide refractoriness (len-R), developed by all our patients during maintenance therapy, and to a higher proportion of patients with extramedullary disease present in our series, which was identified as the only factor significantly affecting the PFS in multivariable analysis. The median overall survival was not reached, as in the pivotal trial, while the 1-year survival probability was 85.1%. Regarding the safety profile, our findings were consistent with those of the IKEMA trial, with no new safety signals reported. Conclusions: These real-world data support the use of IsaKd as a valuable option for len-R MM patients relapsing after the first-line therapy, including ASCT and lenalidomide maintenance.

Keywords: autologous stem cell transplantation; first-relapsed multiple myeloma; isatuximab–carfilzomib–dexamethasone; lenalidomide resistance; second-line therapy.

PubMed Disclaimer

Conflict of interest statement

P.M. has received honoraria from and served on the advisory boards for: Celgene, Janssen, Takeda, Bristol Myers Squibb (BMS), Amgen, Novartis, Gilead, Jazz, Sanofi, AbbVie, and GlaxoSmithKline (GSK). M.T.P. has received honoraria from and served on the advisory boards for: Janssen, BMS, Amgen, Sanofi, GSK, Takeda, Oncopeptides, Pfizer, Menarini, AbbVie. F.D.R. has received onoraria from: GSK, Sanofi, Amgen, Pfizer, and Abbvie. All other authors have declared no conflicts of interest.

Figures

Figure 1
Figure 1
Treatment efficacy.
Figure 2
Figure 2
Progression-free survival (A) and overall survival (B).
See this image and copyright information in PMC

References

    1. Merz M., Dechow T., Scheytt M., Schmidt C., Hackanson B., Knop S. The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma. Ann. Hematol. 2020;99:1709–1725. doi: 10.1007/s00277-020-04023-4. - DOI - PMC - PubMed
    1. Moreau P., Zamagni E., Mateos M.V. Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. Blood Cancer J. 2019;9:38. doi: 10.1038/s41408-019-0200-1. - DOI - PMC - PubMed
    1. Botta C., Martino E.A., Conticello C., Mendicino F., Vigna E., Romano A., Palumbo G.A., Cerchione C., Martinelli G., Morabito F., et al. Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens. Front. Oncol. 2021;11:643490. doi: 10.3389/fonc.2021.643490. - DOI - PMC - PubMed
    1. Palumbo A., Chanan-Khan A., Weisel K., Nooka A.K., Masszi T., Beksac M., Spicka I., Hungria V., Munder M., Mateos M.V., et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N. Engl. J. Med. 2016;375:754–766. doi: 10.1056/NEJMoa1606038. - DOI - PubMed
    1. Richardson P.G., Oriol A., Beksac M., Liberati A.M., Galli M., Schjesvold F., Lindsay J., Weisel K., White D., Facon T., et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): A randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:781–794. doi: 10.1016/S1470-2045(19)30152-4. - DOI - PubMed

LinkOut - more resources